WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 201891

CAS#: 227963-15-7 (free)

Description: MK-0429 is a potent and selective inhibitor of the αvβ3 integrin, which showed therapeutic effects on bone turnover disease in men with hormone-refractory prostate cancer (HRPC) and bone metastases. MK-0429 was safe and efficacious in significantly decreasing melanoma metastasis in the lungs. MK-0429 may be useful for the prevention of metastatic melanoma.

Chemical Structure

CAS# 227963-15-7 (free)

Theoretical Analysis

MedKoo Cat#: 201891
Name: MK-0429
CAS#: 227963-15-7 (free)
Chemical Formula: C23H29N5O4
Exact Mass: 439.22195
Molecular Weight: 439.51
Elemental Analysis: C, 62.85; H, 6.65; N, 15.93; O, 14.56

Size Price Shipping out time Quantity
Inquire bulk and customized quantity

Pricing updated 2021-03-03. Prices are subject to change without notice.

MK-0429 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Related CAS #: 477841-10-4 (5 hydrate)   227963-15-7 (free)   477841-08-0 (2 hydrate)   477841-09-1 (4 hydrate)   1125471-59-1 (0.5 hydrate)    

Synonym: MK-0429; MK 0429; MK0429; L-000845704; L 000845704; L000845704.

IUPAC/Chemical Name: (S)-3-(6-methoxypyridin-3-yl)-3-(2-oxo-3-(3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl)imidazolidin-1-yl)propanoic acid


InChi Code: InChI=1S/C23H29N5O4/c1-32-20-9-7-17(15-25-20)19(14-21(29)30)28-13-12-27(23(28)31)11-3-5-18-8-6-16-4-2-10-24-22(16)26-18/h6-9,15,19H,2-5,10-14H2,1H3,(H,24,26)(H,29,30)/t19-/m0/s1


white solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 439.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Pickarski M, Gleason A, Bednar B, Duong le T. Orally active αvβ3 integrin
inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep. 2015 Jun;33(6):2737-45.
doi: 10.3892/or.2015.3910. Epub 2015 Apr 9. PubMed PMID: 25872534; PubMed Central
PMCID: PMC4431436.

2: Rosenthal MA, Davidson P, Rolland F, Campone M, Xue L, Han TH, Mehta A, Berd
Y, He W, Lombardi A. Evaluation of the safety, pharmacokinetics and treatment
effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease
activity in men with hormone-refractory prostate cancer and bone metastases. Asia
Pac J Clin Oncol. 2010 Mar;6(1):42-8. doi: 10.1111/j.1743-7563.2009.01266.x.
PubMed PMID: 20398037.

Additional Information